Company · CVS
Healthcare · 1 research article
Delayed up to 15 min · Source: Finnhub · Not investment advice
CVS Health's Q1 2026 Aetna medical benefit ratio of 84.6% and five consecutive earnings beats confirm the turnaround is structural, not seasonal. Caremark's 11% revenue growth and 200bps GLP-1 share gain are the hidden growth engine.
| Company | View | Revenue YoY | EPS YoY | Guidance | Last report | |
|---|---|---|---|---|---|---|
| CVS CVS Health | LONG | +7.3% | — | raised | Aug 5, 2026 | |
| BMY Bristol-Myers Squibb | LONG | +7% | — | raised | Oct 29, 2026 | Compare |
| DHR Danaher | LONG | +8.5% | — | revised | Oct 21, 2026 | Compare |
| HUM Humana | LONG | — | — | — | — | Compare |
| ISRG Intuitive Surgical | LONG | +22% | — | issued | Oct 20, 2026 | Compare |
| LLY Eli Lilly | LONG | +39% | +7% | raised | Oct 29, 2026 | Compare |
| MRK Merck | LONG | — | — | issued | Oct 29, 2026 | Compare |
| PFE Pfizer | LONG | — | — | — | — | Compare |
Growth figures are year-over-year changes extracted automatically from each company's latest earnings release and can contain errors.
Widgets by TradingView. They load only when you click, so the page stays fast.
Forensic equity research on US stocks. No spam, unsubscribe anytime.
